The review articles in this issue provide an improved appreciation for microRNA (miRNA)
as an essential feature of lineage commitment and regulatory guidance during tissue
development that, when absent or hampered, often lead to disease states. In the coming
years, there is much to be learned about adaptive (and maladaptive) states by examining
how the expression of miRNAs is influenced by the genetic architecture of miR genes,
clusters, and mirtrons, as well as miRNA polymorphism and polymorphism in their mRNA
targets. We are also introduced to several modes of miRNA regulation (negative feedback,
positive feedback, and cross regulatory) that monitor, modulate, or resolve signaling
pathways in a variety of biologic processes that include sepsis response, fibrosis,
acute exercise, and steroid biology. Perhaps the homeostasis or micromanagement of
these miRNA regulatory systems, when perturbed, arrive at new stable networked interactions
that have an undesired effect of promoting or antagonizing disease severity and cancer
progression. Clearly, a better understanding of these miRNA regulatory networks, as
well as improved therapeutic tools for guiding miRNA expression and their targets
toward desired outcomes, will be the subject of many advances in miRNA biology over
the coming years.
Abbreviations:
IGF-1 (insulin growth factor-1), IRAK1 (interleukin-1 receptor associated kinase 1), LNA (locked nucleic acid), LPS (lipopolysaccharide), MKP-1 (MAP kinase phosphatase-1), miRNA (microRNA), RA (rheumatoid arthritis), RISC (RNA inducing silencing complex), SNP (single-nucleotide polymorphism), TGF-β (tumor necrosis factor β), TRAF6 (TNF receptor-associated factor 6), UTR (untranslated region)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diabetes mellitus, a microRNA-related disease?.Trans Res. 2011; 157: 253-264
- MicroRNAs and liver disease.Trans Res. 2011; 157: 241-252
- Functions and regulation of RNA editing by ADAR deaminases.Annu Rev Biochem. 2010; 79: 321-349
- MicroRNA, a new paradigm for understanding immunoregulation, inflammation and autoimmune diseases.Trans Res. 2011; 157: 163-179
- MicroRNA as therapeutic targets in cancer.Trans Res. 2011; 157: 216-225
- MicroRNAs: genomics, biogenesis, mechanism, and function.Cell. 2004; 116: 281-297
- Involvement of microRNAs in lung cancer biology and therapy.Trans Res. 2011; 157: 200-208
- MicroRNAs in cardiac disease.Trans Res. 2011; 157: 226-235
- MicroRNAs in kidney function and disease.Trans Res. 2011; 157: 236-240
- RNA surveillance-an emerging role for RNA regulatory networks in aging.Ageing Res Rev. 2011; 10: 216-224
- Integrating microRNAs into a system biology approach to acute lung injury.Trans Res. 2011; 157: 180-190
- A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep.Nat Genet. 2006; 38: 813-818
- MicroRNAs: target recognition and regulatory functions.Cell. 2009; 136: 215-233
- A microRNA imparts robustness against environmental fluctuation during development.Cell. 2009; 137: 273-282
- MicroRNAs in idiopathic pulmonary fibrosis.Trans Res. 2011; 157: 191-199
- MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium.Proc Natl Acad Sci U S A. 2009; 106: 2319-2324
- MicroRNA biomarkers in lung cancer: miRacle or quagMiRe?.Trans Res. 2011; 157: 209-215
Article info
Publication history
Published online: February 11, 2011
Identification
Copyright
© 2011 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
